Ratings MariMed Inc.

Equities

MRMD

US56782V1070

Market Closed - OTC Markets 03:56:10 2024-04-26 pm EDT 5-day change 1st Jan Change
0.2666 USD -0.22% Intraday chart for MariMed Inc. -1.26% -2.98%

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • The opinion of analysts covering the stock has improved over the past four months.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

  • The group shows a rather high level of debt in proportion to its EBITDA.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Drug Retailers

1st Jan change Capi. Investor Rating ESG Refinitiv
-2.98% 101M -
+13.25% 2.91B
D+
+14.12% 1.69B -
+84.57% 625M -
+3.64% 485M -
+29.11% 159M -
+13.51% 108M - -
+52.81% 56.96M - -
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
-
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision
-

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality